[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368094-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368094-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","whats-hidden-in-plain-sight-impact-of-clonal-hematopoiesis-on-the-risk-and-progression-of-nonhematologic-cancers","What’s hidden in plain sight? Impact of clonal hematopoiesis on the risk and progression of nonhematologic cancers","","Clonal hematopoiesis (CH) affects aging individuals and is also more common among cancer patients. Mechanistic evidence links CH-associated mutant immune cells to a tumor microenvironment shift, including increased inflammation, angiogenesis, and immune exhaustion, while also maintaining stem-like T-cell pools that may support immunotherapy. Clinically, CH raises therapy-related myeloid neoplasm risk and cardiovascular and inflammatory toxicities, and tumor-infiltrating CH can shorten survival. The paper outlines a pragmatic strategy: confirm CH with paired sequencing, incorporate high-risk features into stratification and monitoring, and choose less genotoxic regimens when benefit is comparable.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/whats-hidden-in-plain-sight-impact-of-clonal-hematopoiesis-on-the-risk-and-progression-of-nonhematologic-cancers/368094/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/whats-hidden-in-plain-sight-impact-of-clonal-hematopoiesis-on-the-risk-and-progression-of-nonhematologic-cancers/368094.png","ImageObject",300,407,{"name":42,"@type":43},"MrHarris58","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is clonal hematopoiesis (CH) and why is it clinically important?","Question",{"text":63,"@type":64},"CH is detectable expansion of a hematopoietic stem cell-derived clone. It increases risks of hematologic malignancies and contributes to cardiovascular and inflammatory toxicities, and in solid tumors it can influence outcomes and survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do CHIP and CCUS differ in their clinical context?",{"text":68,"@type":64},"CHIP refers to somatic mutations in leukemia-associated driver genes at VAF ≥ 2% in individuals without cytopenias or a diagnosed hematologic disorder. CCUS involves similar mutations occurring with persistent unexplained cytopenias but without meeting myelodysplastic syndrome diagnostic criteria.",{"name":70,"@type":61,"acceptedAnswer":71},"How should suspected CH be confirmed and used to guide patient management?",{"text":72,"@type":64},"The paper recommends confirming CH with paired blood sequencing when feasible. It also advises integrating high-risk features into risk stratification, counseling, and monitoring for cytopenias and cardiovascular events, and preferring less genotoxic regimens when oncologic benefit is comparable.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368094,1790196132,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","REVIEW SERIES  \nWhat’s hidden in plain sight? Impact ofclonal hematopoiesis on the risk and progression of nonhematologic cancers  \nJosé C. Martínez1,2 and Catherine C. Coombs3  \n1 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; 2 Division of Hematology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC and 3 Department of Medicine, University of California Irvine Health, Orange, CA, USA  \nCorrespondence: C. Coombs  \n[coombsc@hs.uci.edu](coombsc@hs.uci.edu)  \nReceived: May 31, 2025.  \nAccepted: August 27, 2025.  \nEarly view: September 4, 2025.  \n[https://doi.org/10.3324/haematol.2025.287424](https://doi.org/10.3324/haematol.2025.287424)  \n©2026 Ferrata Storti Foundation  \nPublished under a CC BY-NC license   \nAbstract  \nClonal hematopoiesis (CH) is a frequently observed phenomenon in aging individuals without apparent illness and exhibitsan increased prevalence in cancer patients. Mechanistic studies indicate that mutant immune cells alter the tumor microenvironment, leading to increased inflammation, blood vessel formation, and immune cell exhaustion. Paradoxically, these changes also preserve stem-like T-cell pools that can be utilized by immunotherapy. CH may be incidentally detected inpatients whose solid tumors are profiled by next-generation sequencing. Clinically, CH confers higher risks of therapy-related myeloid neoplasms, cardiovascular and inflammatory toxicities, and context-specific changes in treatment efficacy. Moreover, tumor-infiltrating CH independently shortens survival. Two validated risk scores can inform the risk for myeloid malignancy, yet surveillance, cardiometabolic management, and regimen selection still primarily rely on expert consensus. Because CH may be discovered incidentally, rigorous confirmation of variant origin when CH is suspected is essential to avoid misdirected therapy. We propose a pragmatic approach: (i) confirm CH with paired blood sequencing when feasible; (ii) integrate high-risk features into risk stratification, counseling, and monitoring for cytopenias and cardiovascular events; and (iii) prefer less genotoxic regimens when the oncologic benefit is comparable. Early trials blocking interleukin-1β suggest that targeting inflammation driven by CH may improve outcomes in patients with solid tumors. Prospective studies informed by mutation analysis and tracking clonal changes and inflammatory markers are needed to determine whether routine CH assessment can be integrated into precision oncology to improve outcomes for patients with solid tumors and CH.  \nIntroduction  \nIn the early 1960s, Mary Lyon’s discovery of random X-chromosome inactivation provided a clever genetic “barcode,”enabling investigators to trace the clonality of cell populations with unprecedented precision 1-3 Using this principle, Philip Fialkow and colleagues provided the first convincing evidence demonstrating the clonal origin of chronic myeloid leukemia.4 Similar lineage-tracing studies revealed that even healthy adults, particularly aging women, harbor skewed, clonally restricted hematopoiesis.5,6 These experiments demonstrated that the clonal expansion of hematopoietic stem cells can occur with age but did not identify the genetic drivers of this clonality.  \nWe now understand that most cancers arise from somat-  \nic mutations that quietly accumulate in tissue-specific stem cells as they divide throughout life.7,8 Most of these mutations appear long before a tumor develops and do not portend malignant transformation.9-11 In hematopoietic stem cells, the steady accrual of single-base changes, small insertions/deletions, and larger structural variants creates a genetically diverse pool of progenitors. The gap between skewed X-inactivation and the driver of clonal hematopoiesis (CH) emerged with the discovery of somatic TET2 mutations in aging women 12 Additional work tracing somatic mutations in the pre","cbCaimDJMMXOFHoX","https://ap.wps.com/l/cbCaimDJMMXOFHoX","pdf",1232125,14,"English","# Abstract\n# Introduction\n## Historical foundations of clonal tracing\n## Somatic mutations and emergence of CH\n# CH definitions and clinical implications\n## CHIP and CCUS\n## Links to hematologic and nonhematologic morbidity\n# CH in solid tumors and mechanisms\n## Clonal burden, gene/type, and TME infiltration\n# Review scope and objectives","[{\"question\":\"What is clonal hematopoiesis (CH) and why is it clinically important?\",\"answer\":\"CH is detectable expansion of a hematopoietic stem cell-derived clone. It increases risks of hematologic malignancies and contributes to cardiovascular and inflammatory toxicities, and in solid tumors it can influence outcomes and survival.\"},{\"question\":\"How do CHIP and CCUS differ in their clinical context?\",\"answer\":\"CHIP refers to somatic mutations in leukemia-associated driver genes at VAF ≥ 2% in individuals without cytopenias or a diagnosed hematologic disorder. CCUS involves similar mutations occurring with persistent unexplained cytopenias but without meeting myelodysplastic syndrome diagnostic criteria.\"},{\"question\":\"How should suspected CH be confirmed and used to guide patient management?\",\"answer\":\"The paper recommends confirming CH with paired blood sequencing when feasible. It also advises integrating high-risk features into risk stratification, counseling, and monitoring for cytopenias and cardiovascular events, and preferring less genotoxic regimens when oncologic benefit is comparable.\"}]","What’s hidden in plain sight? Impact of clonal hematopoiesis on the risk and progression of nonhematologic cancers | PDF",1790174990,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd54a8b3865206ea378cfa750c0d7d8a.webp",983,1309,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aaf13e01d52bea5328efed034aa83b9f.webp",982,1308,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d136b150e8035f64ac1fc58e8f716dae.webp",981,1306,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e909f9983cfbd213606e267b2df7a310.webp",980,1305]